Neaodjuvant use of carboplatin – pro
William M. Sikov et al, Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) Journal of Clinical Oncology 33, no. 1 (January 2015) 13-21.
https://www.nccn.org/ordertemplates/default.asp?did=106, 2016
A recent abstract by Sikov suggested further research on the role of carboplatin: ” In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, but whether this will improve relapse-free or overall survival is unknown. Given results from recently reported adjuvant trials, further investigation of bevacizumab in this setting is unlikely, but the role of carboplatin could be evaluated in definitive studies, ideally limited to biologically defined patient subsets most likely to benefit from this agent.”
Gunter von Minckwitz et al, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancert Volume 15, No. 7, p747–756, June 2014
William M. Sikov et al, Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) Journal of Clinical Oncology 33, no. 1 (January 2015) 13-21.
https://www.nccn.org/ordertemplates/default.asp?did=106, 2016